Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
But, as Celyad bows out, how do you compete in a field as crowded as this?
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
In the opening months of 2023 Novo Nordisk needs to defend its position, while Daiichi and Astrazeneca await ADC data.
Evaluate Vantage's coverage of the Ash 2022 congress.
Meanwhile, there was bad blood between cell therapy players and their investors.
Lilly’s non-covalent BTK inhibitor shines yet again, blunting the impact of early data with Nurix’s BTK degrader.
Promising but early data with OTL-201 could see the group compete against the likes of Ultragenyx and Lysogene.
Affimed investors find that what goes up must come down, though the stock owes only part of its fall to an Ash presentation.